Multi-Omics and Machine Learning-Based Profiling of Severity Signatures in Mycoplasma Pneumoniae Infection in Children
Guiqiu Li, Ying Wei, Wenzheng Wang, Zhili Hu, Qiaowen Yang, Lili He, Yun Gao, Xiulan LaiiD
Abstract
Mycoplasma pneumoniae pneumonia (MPP) is a common respiratory infection in children, yet the mechanisms driving its progression to severe disease remain poorly understood. This study employs a comprehensive proteomic and metabolomic approach to elucidate severity-related pathways and identify potential biomarkers for improved diagnosis and targeted therapy. By analyzing blood proteomes from 57 pediatric patients with varying MPP severities alongside 10 healthy controls, and integrating multi-omics data from bronchoalveolar lavage fluid (BALF), we uncovered key severity-associated proteins and metabolites linked to inflammatory and metabolic dysregulation. Notably, alterations in L-arginine metabolism, influenced by APAF1 and SERPINB5, were found to modulate the efferocytosis pathway, while ERCC1 and MLH1, crucial components of the Fanconi anemia pathway, were associated with changes in plasmid acid metabolites affecting fatty acid elongation. Machine learning analysis further identified three critical biomarkers--TNFRSF10B, SAT1, and 4-nitrophenol-- that accurately distinguished between mild and severe MPP cases with high sensitivity (0.8) and specificity (1). These findings provide novel insights into the molecular mechanisms underlying severe MPP, highlighting efferocytosis and fatty acid metabolism as key pathways. The identification of severity-specific biomarkers offers a foundation for enhanced diagnostic precision, improved disease stratification, and the development of targeted therapeutic strategies to optimize the management of severe MPP in pediatric patients. HighlightsO_LIIdentified severity signatures in Mycoplasma pneumoniae infection in children. C_LIO_LIConducted the multi-omics analysis of bronchoalveolar lavage fluid (BALF) in children with varying severities of Mycoplasma pneumoniae infection. C_LIO_LIDiscovered biomarkers that effectively distinguish mild from severe Mycoplasma pneumoniae infection. C_LIO_LIFindings offer potential targets to improve the diagnosis and treatment of severe Mycoplasma pneumoniae C_LIO_LIinfection in children. C_LI
02 /Specification & Classification
Click any tag to browse matching papers- Citations
- 6
- FWCI
- 25.72
- Field percentile
- top 1%
- Organism
- Assay
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Biomarkers to distinguish bacterial from viral pediatric clinical pneumonia in a malaria endemic setting
Michael A. Gillette, D.R. Mani, … Dyann F. Wirth·Clinical Infectious DiseasesPeer-reviewed·Dec 12, 2020
- Growth-state as a determinant of in vivo virulence of Mycoplasma pneumoniae
Jeremy Miller, Morgan L. Hunte, … Steven J. Geary·bioRxiv·Oct 8, 2026
- The Pulmonary Microbial Signatures of Early Stages of Severe Infection in Children
Hao Wu, Yinghu Chen, … Shiqiang Shang·bioRxiv·Aug 25, 2025
- Proteomic profiling of the local and systemic immune response to pediatric respiratory viral infections
Emily Lydon, Christina M Osborne, … Peter M. Mourani·mSystemsPeer-reviewed·Nov 29, 2024
- Viral and bacterial infection elicit distinct changes in plasma lipids in febrile children
Xinzhu Wang, Ruud Nijman, … Myra O. McClure·bioRxiv·May 31, 2019
- The reduced prevalence of macrolide resistance in Mycoplasma pneumoniae clinical isolates from pediatric patients in Beijing in 2016
Xiujun Tian, Ran Wei, … Deli Xin·bioRxiv·Jun 7, 2018